PT3293201T - Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro - Google Patents

Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro

Info

Publication number
PT3293201T
PT3293201T PT161883012T PT16188301T PT3293201T PT 3293201 T PT3293201 T PT 3293201T PT 161883012 T PT161883012 T PT 161883012T PT 16188301 T PT16188301 T PT 16188301T PT 3293201 T PT3293201 T PT 3293201T
Authority
PT
Portugal
Prior art keywords
treating cancer
checkpoint inhibitors
adenovirus
combining
combining adenovirus
Prior art date
Application number
PT161883012T
Other languages
English (en)
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Oy filed Critical Targovax Oy
Publication of PT3293201T publication Critical patent/PT3293201T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT161883012T 2016-09-12 2016-09-12 Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro PT3293201T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16188301.2A EP3293201B1 (en) 2016-09-12 2016-09-12 Combining adenovirus and checkpoint inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
PT3293201T true PT3293201T (pt) 2020-12-07

Family

ID=56926041

Family Applications (1)

Application Number Title Priority Date Filing Date
PT161883012T PT3293201T (pt) 2016-09-12 2016-09-12 Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro

Country Status (14)

Country Link
US (2) US10940203B2 (pt)
EP (2) EP3783032A1 (pt)
JP (2) JP7146739B2 (pt)
CN (1) CN109715664A (pt)
AU (1) AU2017324482A1 (pt)
DK (1) DK3293201T3 (pt)
ES (1) ES2845690T3 (pt)
HR (1) HRP20210133T1 (pt)
HU (1) HUE053236T2 (pt)
LT (1) LT3293201T (pt)
PL (1) PL3293201T3 (pt)
PT (1) PT3293201T (pt)
SI (1) SI3293201T1 (pt)
WO (1) WO2018046803A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
CN110072550A (zh) * 2016-11-01 2019-07-30 德那翠丝有限公司 用于治疗脑癌的组合疗法
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN113573729A (zh) 2019-01-10 2021-10-29 詹森生物科技公司 前列腺新抗原及其用途
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc calr and jak2 mutant-based vaccines and their uses
CN114426945B (zh) * 2021-11-10 2024-08-23 西安交通大学医学院第一附属医院 胶质瘤类器官原代促活液、培养液及制备、培养方法
WO2024207425A1 (en) * 2023-04-07 2024-10-10 Virogin Biotech (Shanghai) Ltd. Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
CA2748180C (en) 2008-12-22 2017-06-20 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI20090030A0 (fi) * 2009-02-02 2009-02-02 Akseli Eetu Hemminki Onkolyyttiset virukset
PT3381942T (pt) 2012-08-30 2021-05-24 Amgen Inc Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário
WO2014047350A1 (en) 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US20160289645A1 (en) * 2013-11-22 2016-10-06 Dnatrix, Inc. Adenovirus Expressing Immune Cell Stimulatory Receptor Agonist(s)

Also Published As

Publication number Publication date
SI3293201T1 (sl) 2021-03-31
HUE053236T2 (hu) 2021-06-28
HRP20210133T1 (hr) 2021-03-19
JP7146739B2 (ja) 2022-10-04
CN109715664A (zh) 2019-05-03
ES2845690T3 (es) 2021-07-27
US20190201525A1 (en) 2019-07-04
DK3293201T3 (da) 2020-12-07
US10940203B2 (en) 2021-03-09
LT3293201T (lt) 2021-03-25
WO2018046803A1 (en) 2018-03-15
EP3783032A1 (en) 2021-02-24
JP2022183170A (ja) 2022-12-08
US11690913B2 (en) 2023-07-04
JP2019532047A (ja) 2019-11-07
US20210121564A1 (en) 2021-04-29
PL3293201T3 (pl) 2021-06-14
EP3293201B1 (en) 2020-11-04
AU2017324482A1 (en) 2019-04-11
EP3293201A1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
IL272470A (en) Methods and materials for the evaluation and treatment of cancer
IL267247B (en) Compositions and methods for treating cancer
HK1245677A1 (zh) 用於治療炎症和癌症的雜環itk抑制劑
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
HK1251862A1 (zh) 治療癌症的方法和組合物
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
HK1248602A1 (zh) 治療癌症的組合物及方法
PT3293201T (pt) Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro
IL270511A (en) Combined treatments using niraparib and pembrolizumab for the treatment of cancer
IL271019A (en) Tinostemustine for the treatment of ovarian cysts
EP3271483A4 (en) Methods and materials for assessing and treating cancer
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3672619A4 (en) MATERIALS AND METHODS FOR EVALUATING CANCER RISK AND TREATING CANCER
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
PL3290051T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
EP3273970A4 (en) Methods and materials for treating cancer
ZA201802268B (en) Methods and compositions for preventing or treating cancer
IL274714A (en) Methods and materials for cancer assessment and treatment
HK1250958A1 (zh) 用於治療癌症的組合物和方法
IL255541A (en) Cabazitaxel and its use for treating cancer
HUE057064T2 (hu) RAD1901 petefészekrák kezelésében történõ alkalmazásra
PL3402889T3 (pl) Skojarzenie adenowirusa i środków chemioterapeutycznych do leczenia raka
GB201609402D0 (en) Materials and methods for treating cancer
GB201720089D0 (en) Means and methods for treating cancer